Quantcast

Latest Boehringer Ingelheim Pharmaceuticals Inc. Stories

2014-08-26 08:31:41

New JARDIANCE Simple Savings program currently offered in doctors' offices and online RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 26, 2014 /PRNewswire/ -- Jardiance(®) (empagliflozin) tablets are now available by prescription in pharmacies across the United States, including Walgreens, Rite Aid, Kroger and many other leading chain and independent retailers, according to Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY). The U.S. Food and Drug Administration...

2014-08-25 08:27:31

Hot Line session presentations to feature renal function data from pivotal RE-LY® trial and global GLORIA(TM)-AF registry updates RIDGEFIELD, Conn., Aug. 25, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that data from nine company-sponsored Pradaxa® (dabigatran etexilate mesylate) studies will be presented at the European Society of Cardiology (ESC) Congress 2014, August 30 to September 3 in Barcelona, Spain. The abstracts will feature data about the use...

2014-08-19 12:28:32

For U.S. Media Only RIDGEFIELD, Conn., Aug. 19, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) accepted for review the New Drug Application (NDA) for the fixed-dose combination (FDC) of tiotropium and olodaterol delivered via the Respimat(®) inhaler for the proposed indication of long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including...

2014-08-18 20:21:55

INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar(TM) (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes. Basaglar is not recommended for the treatment of diabetic ketoacidosis. Basaglar is Eli Lilly and Company (NYSE: LLY) and...

2014-08-14 16:27:26

Committee Voted Based on Clinical Data from Eight Efficacy Trials RIDGEFIELD, Conn., Aug. 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted [10 yes, 3 no] that existing data supports approval of Boehringer Ingelheim's investigational tiotropium bromide inhalation spray for long-term, once-daily maintenance treatment of bronchospasm associated...

2014-08-04 08:29:23

- Combination of linagliptin and metformin significantly reduced blood glucose levels compared with linagliptin alone RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 4, 2014 /PRNewswire/ -- The U.S. Prescribing Information for Jentadueto® (linagliptin and metformin hydrochloride) tablets now includes clinical trial data that showed linagliptin co-administered with metformin provided statistically significant decreases in blood glucose compared with linagliptin alone in treatment-naive* adults with...

2014-08-02 00:21:08

Third product from the BI-Lilly Diabetes alliance to be approved by FDA RIDGEFIELD, Conn., and INDIANAPOLIS, Aug. 1, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Jardiance® (empagliflozin) tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes (T2D). JARDIANCE is not for people with type 1...

2014-08-01 08:26:18

For U.S. Media Only RIDGEFIELD, Conn., Aug. 1, 2014 /PRNewswire/ -- Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has approved Striverdi(®) Respimat(®) (olodaterol) Inhalation Spray 5 mcg as a long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. STRIVERDI RESPIMAT is not indicated to treat acute...

2014-07-23 16:26:55

British Medical Journal publishes biased article regarding PRADAXA RIDGEFIELD, Conn., July 23, 2014 /PRNewswire/ -- Boehringer Ingelheim (BI) wants to set the record straight following misleading statements that the British Medical Journal (BMJ) published today regarding Pradaxa® (dabigatran etexilate mesylate). We are concerned that this publication may alarm patients and prompt them to stop taking PRADAXA, thereby increasing their risk of stroke. To be clear, many of the allegations made...

2014-07-16 12:28:07

For U.S. Media Only RIDGEFIELD, Conn., July 16, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted Breakthrough Therapy designation to nintedanib, an investigational therapy currently under FDA review for the treatment of people with idiopathic pulmonary fibrosis (IPF). The efficacy and safety of nintedanib in the treatment of IPF has not been established. "Boehringer Ingelheim is proud that...


Word of the Day
cock-a-hoop
  • Exultant; jubilant; triumphant; on the high horse.
  • Tipsy; slightly intoxicated.
This word may come from the phrase 'to set cock on hoop,' or 'to drink festively.' Its origin otherwise is unclear. A theory, according to the Word Detective, is that it's a 'transliteration of the French phrase 'coq a huppe,' meaning a rooster displaying its crest ('huppe') in a pose of proud defiance.' Therefore, 'cock-a-hoop' would 'liken a drunken man to a boastful and aggressive rooster.'
Related